FTC review periods end for AbbVie-ImmunoGen $10.1B deal and $4B BMS-RayzeBio buyout

AbbVie moved ahead with its $10.1 billion acquisition of antibody-drug conjugate biotech ImmunoGen, while Bristol Myers Squibb’s big acquisition of radiopharmaceuticals biotech RayzeBio is likely on the way too, despite the Federal Trade Commission’s heightened attention on pharma M&A.

AbbVie announced the closure…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks